Neuromuscular Disease
Dystrogen Therapeutics Technology Polska Sp. z o.o. is focused on clinical research in Duchenne Muscular Dystrophy, with interest in the progression of muscle weakness, loss of motor function, and disease-related impairment across different stages of the condition.
- Duchenne Muscular Dystrophy
- Muscle weakness
- Motor function impairment
The sponsor’s research activity is centered on patient groups with both ambulatory and non-ambulatory disease profiles, reflecting attention to functional status in a severe inherited muscular disorder.
Muscle Function Assessment
The clinical program places emphasis on measuring muscle strength and functional performance in everyday movement, including walking ability, rising from a supine position, and upper-limb function in advanced disease.
- Six-Minute Walk Test
- NorthStar Ambulatory Assessment
- PUL 2.0
These areas of interest indicate a strong therapeutic focus on preserving mobility and evaluating functional capacity in neuromuscular disease.
Electrophysiology
Research activity also includes electromyography assessment, with attention to motor unit potential characteristics in selected muscles as part of the evaluation of disease impact on skeletal muscle.
- Electromyography
- Motor unit potential
- Skeletal muscle
This reflects interest in objective physiological markers of muscle integrity and neuromuscular involvement.
Safety and Tolerability
The sponsor’s clinical work includes close attention to treatment-related safety in patients with Duchenne Muscular Dystrophy, with monitoring of adverse events and other clinically relevant risks.
- Adverse Events
- Serious Adverse Events
- Adverse Events of Special Interest
This safety focus is linked to the development of therapies intended for a progressive genetic muscle disease.
